All Supplement articles
View all stories of the same content type.
-
SupplementSupporting patients with joint pain in community pharmacy
This content is intended for UK healthcare professionals only.
PM-UK-VOLT-20-00192 Date of preparation: January 2021 -
Supplement
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103452 Date of preparation: January 2021 -
Supplement
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines for Nurses.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103453 Date of preparation: January 2021 -
Supplement
Prescribing hormone replacement therapy (HRT) in postmenopausal women: a focus on Oestrogel® (estradiol) and Utrogestan® 100 mg (micronised progesterone)
This prescribing supplement has been commissioned and funded by Besins Healthcare (UK) Ltd and developed in partnership with Guidelines. Includes promotional information.
View prescribing and adverse event reporting information
OES/2021/001 February 2021
For healthcare professionals only. -
Supplement
Recommending emollients for patients with atopic dermatitis or dry skin conditions
This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines.
Date of preparation: January 2021 -
Supplement
The importance of the progestogenic component of hormone replacement therapy in women with a uterus
Dr John Stevenson and Dr Sophia Tsiligiannis discuss progestogen prescribing in hormone replacement therapy.
